Special Issue

Genomic Instability and How to Exploit It for Cancer Cell Vulnerability

Message from the Guest Editor

Genomic Instability is a major source of both variation required for the clonal evolution of cancer and the resulting intratumoral heterogeneity (ITH). This in turn drives tumor growth and acts as a significant barrier to effective cancer therapies. In this Special Issue, we invite original research articles and reviews related to some of the prevailing questions regarding genomic instability in cancer: How do cancer cells develop tolerance to damage insinuated by progressive instability? Which genes and regulatory regions within SCNAs and aneuploidies enable this tolerance and promote cancer cell fitness? Which stress-response barriers in the natural history of tumor evolution cancer cells must overcome by selecting for fitness-promoting SCNAs and aneuploid regions? Which structural alterations are a result of selective pressures induced by either the tumor immune microenvironment or cancer therapies (i.e., to identify the SCNAs driving recurrent or treatment-resistant metastatic cancers)?

Guest Editor

Dr. Samir B. Amin
The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA

Deadline for manuscript submissions

closed (22 September 2022)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/91061

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)